

Cat. No.: GC49677

Chemical Properties

Cas. No. 1185144-74-4

SMILES OC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C1=C(C(O)=O)N(CC(C=C2)=CC=C2C3=C(C4=NN=NN4)C=CC=C3)C(CCC)=N1


Formula	C ₂₄ H ₂₀ D ₆ N ₆ O ₃	M.Wt	452.5
---------	--	------	-------

Solubility	DMSO: soluble	Storage	-20°C
------------	---------------	---------	-------

General tips	For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
--------------	---

Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.
--------------------	--

Structure



Background

Olmesartan-d₆ is intended for use as an internal standard for the quantification of olmesartan by GC-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@qlpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

or LC-MS. Olmesartan is a non-peptide angiotensin II receptor 1 (AT₁) antagonist (IC₅₀ = 0.0077 µM for the bovine adrenal cortex receptor) and an active metabolite of olmesartan medoxomil.¹ It is formed from olmesartan medoxomil by paraoxonase 1 (PON1) in human plasma.² Olmesartan is selective for AT₁ over AT₂ (IC₅₀ = >100 µM for the bovine cerebellar receptor). It reduces contraction of isolated guinea pig aorta induced by angiotensin II but not phenylephrine or potassium chloride. Olmesartan (0.01 and 0.03 mg/kg, i.v.) reduces the angiotensin II-induced pressor response in conscious normotensive rats.

1. Mizuno, M., Sada, T., Ikeda, M., et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. *Eur. J. Pharmacol.* 285(2):181-188 (1995).
2. Ishizuka, T., Fujimori, I., Nishida, A., et al. Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: Molecular identification and contribution to plasma metabolism. *Drug Metab. Dispos.* 40(2):374-380 (2012).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA